(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) |
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
SUPERNUS PHARMACEUTICALS, INC. | ||||||||
DATED: April 24, 2024 | By: | /s/ Timothy C. Dec | ||||||
Timothy C. Dec | ||||||||
Senior Vice President and Chief Financial Officer |
Cover Page |
Apr. 22, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | Apr. 22, 2024 |
Entity Registrant Name | Supernus Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity Filer Name | 001-35518 |
Entity Tax Identification Number | 20-2590184 |
Entity Address, Address Line One | 9715 Key West Ave |
Entity Address, City or Town | Rockville |
Entity Address, State or Province | MD |
Entity Address, Postal Zip Code | 20850 |
City Area Code | 301 |
Local Phone Number | 838-2500 |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | SUPN |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Amendment Flag | false |
Entity Central Index Key | 0001356576 |
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end
5[Y0([FZ9^@4@>GH-S)SUU[YHR
M0WU)E$%-_;9( K4XI+<%7X*O.4E3H]DM?1FQ.KJ\>\CQS)A')I$ZF0MO*%>5
M&Y@K+:P Z\_X3-"* A4-CR5]@!L0(3'#GEKG(*P,;5"_&U!X6>*?S:.O_G;]
M):QU/F3M.ZFVL?ZL7?,CNW:: #+PG<;OE4GQ_[IZWY8![4V[M]%NXP-[Z.MJ#^GDW89Z^VEG8M]L?RJKK/J
MKL=%6?_=&:@1E&G( 2-1#$C*N6'3M%,)0TACDB0<6]]PT24P#HS/FEZSX(N:
MV-+G[]0+/%N3'KAU.QE VHN (T/6;6>;KYYU?6@U*VY@_'[Z:O-,MOICG:>O
M_@=02P,$% @ KH"86++JX6NN!@ ZC !4 !S=7!N+3(P,C0P-#(R
M7W!R92YX;6S5FFU/XT@2Q]_S*7+ C)'SC]%\EV]U<_G*[=G6YR"%C-A<.XZ8"':=8T B;D4SP
M*$7N.*AQN7]D;ECB)]R*?+UX$_G3?[CQ*ULMH>^U*PD>!*I 7>_,M><&."!
M*.=E;H+5UM"]_/$?6AW&P(2[CZ.E?&,4?D?G6ZC.ZO5Z6]VWR)J%C%&)$ -A
MP',BO6+$4&.)